van de Donk, Pim P. http://orcid.org/0000-0002-0003-525X
Wind, Thijs T.
Hooiveld-Noeken, Jahlisa S.
van der Veen, Elly L.
Glaudemans, Andor W. J. M.
Diepstra, Arjan
Jalving, Mathilde
de Vries, Elisabeth G. E.
de Vries, Erik F. J.
Hospers, Geke A. P.
Funding for this research was provided by:
KWF Kankerbestrijding (10034)
ZonMw (95104008)
Genentech
Article History
Received: 19 January 2021
Accepted: 10 May 2021
First Online: 2 June 2021
Declarations
:
: All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Medisch ethische toetsingscommissie UMC Groningen) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Written informed consent was obtained from all individual participants included in the study.
: MJ: advisory board, honoraria to institution: Merck, BMS, Novartis, Pierre Fabre, Tesaro, AstraZeneca. Clinical studies: BMS, AbbVie, Merck, Cristal Therapeutics. GH: consulting and advisory role: Amgen, Roche, MSD, BMS, Pfizer, Novartis, Pierre Fabry, paid to the institution (UMCG). Research grant BMS, Seerave, paid to the institution (UMCG). EdV: Institutional financial support for consulting and advisory role for Sanofi, Daiichi Sankyo, NSABP, Pfizer, Merck, and institutional financial support for clinical trials or contracted research from Amgen, Genentech, Roche, AstraZeneca, Synthon, Regeneron, Bayer, Chugai Pharma, CytomX Therapeutics, Servier, Nordic Nanovector, G1 Therapeutics, Radius Health; all outside the submitted work. No other potential conflicts of interest relevant to this article exist.